| View |
|
BR-1255
|
Menotrophin
|
Humog 75
|
75 IU
|
Solution for Injection
|
GONADOTROPHIN
|
Bharat Biotech International Ltd.
|
India
|
Automatic Renewal
|
16 December 2022
|
04 January 2028
|
| View |
|
BR-1259
|
Chorionic Gonadotrophin
|
Hucog-5,000 Hp
|
5,000 IU
|
Solution For Injection/ 5000 I.U.
|
Gonadotropins
|
Bharat Serums and Vaccine Limited
|
India
|
Automatic Renewal
|
13 December 2022
|
26 January 2028
|
| View |
|
BR-1261
|
Urofollitropin
|
Foliculin -75 HP
|
75 IU
|
Lyophilized Powder for Solution for Injection (IM/SC)
|
Gonadotropins
|
Bharat Serums and Vaccines Limited
|
India
|
Initial
|
18 February 2022
|
05 March 2026
|
| View |
|
BR-1263
|
Diphtheria, Tetanus, Pertussis, Hepatitis B Recombinant and Haemophilus influenza B Tyoe (Hib) Vaccine
|
Eupenta
|
|
Solution for IM Injection
|
Vaccine
|
LG Chem Limited
|
Korea
|
Renewal
|
03 January 2023
|
13 March 2028
|
| View |
|
BR-1264
|
Diphtheria, Tetanus, Pertussis, Hepatitis B Recombinant and Haemophilus influenza B Tyoe (Hib) Vaccine
|
Eupenta
|
|
Solution for IM Injection
|
Vaccine
|
LG Chem Limited
|
Korea
|
Renewal
|
04 January 2023
|
13 March 2028
|
| View |
BR-1266_PI_01.pdf
|
BR-1266
|
Evolocumab
|
Repatha
|
140 mg/mL
|
Solution for Injection in Pre-filled Autoinjector
|
Anti-PCSK9 Monoclonal Antibody
|
Amgen Manufacturing Ltd.
|
U.S.A.
|
Monitored Release
|
23 April 2018
|
23 April 2025
|
| View |
BR-1267_PI_01.pdf
|
BR-1267
|
Evolocumab
|
Repatha
|
140 mg/mL
|
Pre-filled Syringe for Injection
|
Anti-PCSK9 Monoclonal Antibody
|
Amgen Manufacturing Ltd.
|
U.S.A.
|
Monitored Release
|
23 April 2018
|
23 April 2025
|
| View |
|
BR-1268
|
Insulin aspart
|
Fiasp Flextouch
|
100 Units/mL
|
Solution for Injection (SC/IV)
|
-
|
Novo Nordisk A/S
|
Denmark
|
Renewal
|
19 October 2023
|
09 May 2028
|
| View |
|
BR-1269
|
Insulin aspart
|
Fiasp
|
100 Units/mL
|
Solution for Injection (IV/SC)
|
Insulins and Analogues
|
Novo Nordisk A/S
|
Denmark
|
Renewal
|
07 November 2023
|
09 May 2028
|
| View |
BR-1270_PI_01.pdf
|
BR-1270
|
Insulin Glargine/ Lixisenatide
|
Soliqua
|
3.64 mg (equivalent to 100 Units of Insulin glargine) / 50 mcg per mL
|
Solution for Injection (SC)
|
Long-acting Insulin and Analogue.
|
Sanofi-Aventis Deutschland GmbH
|
Germany
|
Initial (from Monitored Release)
|
06 March 2024
|
09 May 2028
|
| View |
BR-1271_PI_01.pdf
|
BR-1271
|
Insulin Glargine/ Lixisenatide
|
Soliqua
|
3.64 mg (equivalent to 100 Units of Insulin glargine) / 33 mcg per mL
|
Solution for Injection (SC)
|
Long-acting Insulin and Analogue
|
Sanofi-Aventis Deutschland GmbH
|
Germany
|
Initial (from Monitored Release)
|
06 March 2024
|
09 May 2028
|
| View |
|
BR-1275
|
Human Albumin
|
Alburx
|
200 g/L (20% w/v)
|
Solution for Intravenous Infusion
|
Plasma fractions for specific uses
|
CSL Behring AG
|
Switzerland
|
BR-1275
|
31 December 2022
|
07 June 2028
|
| View |
|
BR-1276
|
Human Albumin
|
Alburx
|
250 g/L (25 % w/v)
|
Solution for Intravenous Infusion
|
Plasma fractions for specific uses
|
CSL Behring AG
|
Switzerland
|
Automatic Renewal
|
05 January 2023
|
07 June 2028
|
| View |
|
BR-1277
|
Human Albumin
|
Alburx
|
200 g/L (20% w/v)
|
Solution for Intravenous Infusion
|
Plasma fractions for specific uses
|
CSL Behring LLC
|
U.S.A.
|
BR-1277
|
03 January 2023
|
07 June 2028
|
| View |
|
BR-1278
|
Human Albumin
|
Alburx
|
250 g/L (25% w/v)
|
Solution for Intravenous Infusion
|
Plasma fractions for specific uses
|
CSL Behring LLC
|
U.S.A.
|
BR-1278
|
31 December 2022
|
07 June 2028
|
| View |
|
BR-1280
|
Atezolizumab
|
Tecentriq
|
60 mg/mL (1.2 g/20 mL)
|
Concentrate for Solution for
Infusion
|
-
|
Roche Diagnostics GmbH
|
Germany
|
Monitored Release (Variation)
|
22 February 2023
|
22 February 2028
|
| View |
|
BR-1282
|
Eptacog alfa activated
|
NovoSeven RT
|
1 mg/vial (50KIU/vial)
|
Powder And Solvent For Solution For Injection
|
Blood Coagulation Factor
|
Novo Nordisk A/S
|
Denmark
|
Renewal
|
01 August 2023
|
25 July 2028
|
| View |
|
BR-1284
|
Isophane Insulin (Recombinant DNA)
|
Humulin N
|
100 Units/mL
|
Suspension for Injection (SC)
|
-
|
Lilly France S.A.S.
|
France
|
Renewal
|
11 October 2022
|
31 October 2027
|
| View |
|
BR-1290
|
Inactivated Poliomyelitis Vaccine (Types 1, 2 And 3)
|
Poliovac
|
0.5 mL
|
Suspension For Injection (IM/SC)
|
-
|
Serum Institute of India Private Limited
|
India
|
Initial (Variation)
|
09 February 2023
|
09 February 2028
|
| View |
|
BR-1296
|
Dulaglutide
|
Trulicity
|
0.75 mg/0.5 mL
|
Solution For Injection
|
Antidiabetic
|
Eli Lilly and Company
|
United States of America
|
Monitored Release
|
08 October 2019
|
18 June 2025
|